Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’

Published

on

Since stepping in as Sanofi’s CEO in April, Belén Garijo has launched a deep look at the pharma’s pipeline, reassessing assets based on “scientific merit” and potential for long-term value in the quest for a Dupixent follow-up.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: Two FDA approvals — a new drug and a new vaccine

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Again, a child dies in a gene therapy trial in China, and STAT has exclusive details. Also, we have encouraging fecal pill results for peanut allergy, and see biotech investor Greg Verdine notch a series of wins.

In other news, it’s been hot out! My backyard tortoise, Philbert, has been most irascible and taken to his fainting couch (cardboard box).

Continue to STAT+ to read the full story…

Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Again, a child dies in a gene therapy trial in China, and STAT has exclusive details. Also, we have encouraging fecal pill results for peanut allergy, and see biotech investor Greg Verdine notch a series of wins.

In other news, it’s been hot out! My backyard tortoise, Philbert, has been most irascible and taken to his fainting couch (cardboard box).

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

With $263M, LifeMine unearths a new drug for organ transplants

Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs. 

Read More

Published

on

Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs. 

Read More

Continue Reading

Uncategorized

Takeda’s narcolepsy nod opens orexin doors

Published

on

Orzeyful is the first orexin agonist cleared by the FDA, and is the first narcolepsy therapy that addresses the full host of disease symptoms. It is “likely to reshape the treatment paradigm” for the condition, Jefferies told investors.

Continue Reading
Advertisement

Trending